Document:

Exhibit 4.1

 

BA CREDIT CARD TRUST

as Issuer

CLASS A(2018‐2) TERMS DOCUMENT

dated as of May 17, 2018

to

THIRD AMENDED AND RESTATED BASERIES INDENTURE SUPPLEMENT

dated as of December 17, 2015

to

FOURTH AMENDED AND RESTATED INDENTURE

dated as of December 17, 2015

THE BANK OF NEW YORK MELLON

as Indenture Trustee

 

TABLE OF CONTENTS

	 	 	 	
Page

	 	 	 	 
	
ARTICLE I

	
Definitions And Other Provisions Of General Application

	
1

	 	 	 
	 	
Section 1.01.

	
Definitions

	
1

	 	
Section 1.02.

	
Governing Law; Submission to Jurisdiction; Agent for Service of Process

	
5

	 	
Section 1.03.

	
Counterparts

	
6

	 	
Section 1.04.

	
Ratification of Indenture and Indenture Supplement

	
6

	 	 	 
	
ARTICLE II

	
The Class A(2018‐2) Notes

	
7

	 	 	 
	 	
Section 2.01.

	
Creation and Designation

	
7

	 	
Section 2.02.

	
Specification of Required Subordinated Amount and other Terms

	
7

	 	
Section 2.03.

	
Interest Payment

	
7

	 	
Section 2.04.

	
Payments of Interest and Principal

	
8

	 	
Section 2.05.

	
Form of Delivery of Class A(2018‐2) Notes; Depository; Denominations

	
8

	 	
Section 2.06.

	
Delivery and Payment for the Class A(2018‐2) Notes

	
8

	 	
Section 2.07.

	
Targeted Deposits to the Accumulation Reserve Account

	
8

	 	 	 
	
ARTICLE III

	
Representations and Warranties

	
9

	 	 	 
	 	
Section 3.01.

	
Issuer’s Representations and Warranties

	
9

 

- i -

THIS CLASS A(2018‐2) TERMS DOCUMENT (this “Terms Document”), by and between BA CREDIT CARD TRUST, a statutory trust created under the laws of the State of Delaware (the “Issuer”), having its principal office at Rodney Square North, 1100 North Market Street, Wilmington, Delaware 19890, and THE BANK OF NEW YORK MELLON, a New York banking corporation, as Indenture Trustee (the “Indenture Trustee”), is made and entered into as of May 17, 2018.

Pursuant to this Terms Document, the Issuer and the Indenture Trustee shall create a new tranche of Class A Notes and shall specify the principal terms thereof.

ARTICLE I

Definitions and Other Provisions of General Application

 

Section 1.01.          Definitions.  For all purposes of this Terms Document, except as otherwise expressly provided or unless the context otherwise requires:

	 	
(1)

	
the terms defined in this Article have the meanings assigned to them in this Article, and include the plural as well as the singular;

		
(2)

	
all other terms used herein which are defined in the Third Amended and Restated BAseries Indenture Supplement, dated as of December 17, 2015 (as modified, amended or supplemented from time to time, the “Indenture Supplement”), between the Issuer and the Indenture Trustee, or the Fourth Amended and Restated Indenture, dated as of December 17, 2015 (as modified, amended or supplemented from time to time, the “Indenture”), between the Issuer and the Indenture Trustee, as acknowledged and accepted by BANA, as Servicer, either directly or by reference therein, have the meanings assigned to them therein;

		
(3)

	
all accounting terms not otherwise defined herein have the meanings assigned to them in accordance with generally accepted accounting principles and, except as otherwise herein expressly provided, the term “generally accepted accounting principles” with respect to any computation required or permitted hereunder means such accounting principles as are generally accepted in the United States of America at the date of such computation;

		
(4)

	
all references in this Terms Document to designated “Articles,” “Sections” and other subdivisions are to the designated Articles, Sections and other subdivisions of this Terms Document as originally executed;

		
(5)

	
the words “herein,” “hereof” and “hereunder” and other words of similar import refer to this Terms Document as a whole and not to any particular Article, Section or other subdivision;

 

		
(6)

	
in the event that any term or provision contained herein shall conflict with or be inconsistent with any term or provision contained in the Indenture Supplement or the Indenture, the terms and provisions of this Terms Document shall be controlling;

		
(7)

	
each capitalized term defined herein shall relate only to the Class A(2018‐2) Notes and no other tranche of Notes issued by the Issuer; and

		
(8)

	
“including” and words of similar import will be deemed to be followed by “without limitation.”

“Accumulation Reserve Funding Period” shall mean, (a) if the Accumulation Period Length is determined to be one (1) month, there shall be no Accumulation Reserve Funding Period and (b) otherwise, the period (x) commencing on the earliest to occur of (i) the Monthly Period beginning three (3) calendar months prior to the first Transfer Date for which a budgeted deposit is targeted to be made into the Principal Funding sub-Account of the Class A(2018‐2) Notes pursuant to Section 3.10(b) of the Indenture Supplement, (ii) the Monthly Period following the first Transfer Date following and including the March 2019 Transfer Date for which the Quarterly Excess Available Funds Percentage is less than 2%, but in such event the Accumulation Reserve Funding Period shall not be required to commence earlier than 24 months prior to the Expected Principal Payment Date, (iii) the Monthly Period following the first Transfer Date following and including the September 2019 Transfer Date for which the Quarterly Excess Available Funds Percentage is less than 3%, but in such event the Accumulation Reserve Funding Period shall not be required to commence earlier than 18 months prior to the Expected Principal Payment Date, and (iv) the Monthly Period following the first Transfer Date following and including the November 2019 Transfer Date for which the Quarterly Excess Available Funds Percentage is less than 4%, but in such event the Accumulation Reserve Funding Period shall not be required to commence earlier than 16 months prior to the Expected Principal Payment Date and (y) ending on the close of business on the last day of the Monthly Period preceding the earlier to occur of (i) the Expected Principal Payment Date for the Class A(2018‐2) Notes and (ii) the date on which the Class A(2018‐2) Notes are paid in full.

“Base Rate” means, with respect to any Monthly Period, the sum of (i) the Weighted Average Interest Rates for the Outstanding BAseries Notes and the Class D Certificate (as such term is defined in the Series 2001‐D Supplement), (ii) the Net Servicing Fee Rate (as such term is defined in the Series 2001‐D Supplement) and (iii) so long as BANA or The Bank of New York Mellon is the Servicer, the Servicer Interchange Rate, in each case, for such Monthly Period.

“BAseries Servicer Interchange” means, with respect to any Monthly Period, an amount equal to the product of (a) the Servicer Interchange (as such term is defined in the Series 2001‐D Supplement) with respect to such Monthly Period and (b) a fraction the numerator of which is the Weighted Average Available Funds Allocation Amount for the BAseries for such Monthly Period and the denominator of which is the Weighted Average Available Funds Allocation Amount for all series of Notes for such Monthly Period.

 

- 2 -

“Class A(2018‐2) Note” means any Note, substantially in the form set forth in Exhibit A-1 to the Indenture Supplement, designated therein as a Class A(2018‐2) Note and duly executed and authenticated in accordance with the Indenture.

“Class A(2018‐2) Noteholder” means a Person in whose name a Class A(2018‐2) Note is registered in the Note Register.

“Class A(2018‐2) Termination Date” means the earliest to occur of (a) the Principal Payment Date on which the Outstanding Dollar Principal Amount of the Class A(2018‐2) Notes is paid in full, (b) the Legal Maturity Date and (c) the date on which the Indenture is discharged and satisfied pursuant to Article VI thereof.

“Class A Required Subordinated Amount of Class B Notes” is defined in Section 2.02(a). 

“Class A Required Subordinated Amount of Class C Notes” is defined in Section 2.02(b).

“Controlled Accumulation Amount” means $100,000,000; provided, however, if the Accumulation Period Length is determined to be less than twelve (12) months pursuant to Section 3.10(b)(ii) of the Indenture Supplement, the Controlled Accumulation Amount shall be the amount specified in the definition of “Controlled Accumulation Amount” in the Indenture Supplement.

“Excess Available Funds Percentage” means, with respect to any Transfer Date, the amount, if any, by which the Portfolio Yield for the preceding Monthly Period exceeds the Base Rate for such Monthly Period.

“Expected Principal Payment Date” means April 15, 2021.

“Initial Dollar Principal Amount” means $1,200,000,000.

“Interest Payment Date” means the fifteenth day of each month, or if such fifteenth day is not a Business Day, the next succeeding Business Day, commencing July 16, 2018.

“Interest Period” means, with respect to any Interest Payment Date, the period from and including the previous Interest Payment Date (or in the case of the initial Interest Payment Date, from and including the Issuance Date) through the day preceding such Interest Payment Date.

“Issuance Date” means May 17, 2018.

 

- 3 -

“Legal Maturity Date” means September 15, 2023.

“Note Interest Rate” means a per annum rate equal to 3.00%.

“Paying Agent” means The Bank of New York Mellon.

“Portfolio Yield” means, with respect to any Monthly Period, the annualized percentage equivalent of a fraction, the numerator of which is (a) the amount of Available Funds allocated to the BAseries pursuant to Section 501 of the Indenture, plus (b) the amount of Available Funds distributed pursuant to Sections 4.06(a)(ii) and (iii) of the Series 2001‐D Supplement, plus (c) any Interest Funding sub‐Account Earnings on the related Transfer Date, plus (d) any amounts to be treated as BAseries Available Funds pursuant to Sections 3.20(d) and 3.27(a) of the Indenture Supplement, plus (e) the BAseries Servicer Interchange for such Monthly Period, minus (f) the excess, if any, of the sum of the PFA Prefunding Earnings Shortfall plus the PFA Accumulation Earnings Shortfall over the sum of the aggregate amount to be treated as BAseries Available Funds for such Monthly Period pursuant to Sections 3.04(a)(ii) and 3.25(a) of the Indenture Supplement plus any other amounts applied to cover earnings shortfalls on amounts in the Principal Funding sub‐Account for any tranche of BAseries Notes for such Monthly Period, minus (g) the BAseries Investor Default Amount for such Monthly Period, minus (h) the Aggregate Class D Investor Default Amount (as such term is defined in the Series 2001‐D Supplement) for such Monthly Period, and the denominator of which is the Weighted Average Floating Allocation Investor Interest (as such term is defined in the Series 2001‐D Supplement) for such Monthly Period.

“Predecessor Note” means, with respect to any particular Note, every previous Note evidencing all or a portion of the same debt as that evidenced by such particular Note; and, for the purpose of this definition, any Note authenticated and delivered under Section 306 of the Indenture in lieu of a mutilated, lost, destroyed or stolen Note shall be deemed to evidence the same debt as the mutilated, lost, destroyed or stolen Note.

“Quarterly Excess Available Funds Percentage” means, with respect to the March 2019 Transfer Date and each Transfer Date thereafter, the percentage equivalent of a fraction the numerator of which is the sum of the Excess Available Funds Percentages with respect to the immediately preceding three Monthly Periods and the denominator of which is three.

“Record Date” means, for any Transfer Date, the last day of the preceding Monthly Period.

“Required Accumulation Reserve sub-Account Amount” means, with respect to any Monthly Period during the Accumulation Reserve Funding Period, an amount equal to (i) 0.5% of the Outstanding Dollar Principal Amount of the Class A(2018‐2) Notes as of the close of business on the last day of the preceding Monthly Period or (ii) any other amount designated by the Issuer; provided, however, that if such designation is of a lesser amount, the Note Rating Agencies shall have provided prior written confirmation that a Ratings Effect will not occur with respect to such change.

 

- 4 -

“Servicer Interchange Rate” means, for any Monthly Period, the percentage equivalent of a fraction, the numerator of which is the BAseries Servicer Interchange for such Monthly Period, and the denominator of which is the Weighted Average Floating Allocation Investor Interest (as such term is defined in the Series 2001‐D Supplement) for such Monthly Period.

“Stated Principal Amount” means $1,200,000,000.

“Weighted Average Interest Rates” means, with respect to any Outstanding Notes of a class or tranche of the BAseries or the Class D Certificate (as such term is defined in the Series 2001‐D Supplement), or of all of the Outstanding Notes of the BAseries and the Class D Certificate, on any date, the weighted average (weighted based on the Outstanding Dollar Principal Amount of the related Notes on such date or, in the case of the Class D Certificate, based on the Class D Investor Interest (as such term is defined in the Series 2001‐D Supplement) on such date) of the following rates of interest:

(a)       in the case of the Class D Certificate or a tranche of Dollar Interest-bearing Notes with no Derivative Agreement for interest, the rate of interest applicable to that tranche or the Class D Certificate on that date;

(b)       in the case of a tranche of Discount Notes, the rate of accretion (converted to an accrual rate) of that tranche on that date;

(c)       in the case of a tranche of Notes with a payment due under a Performing Derivative Agreement for interest, the rate at which payments by the Issuer to the applicable Derivative Counterparty accrue on that date (prior to the netting of such payments, if applicable); and 

(d)       in the case of a tranche of Notes with a non-Performing Derivative Agreement for interest, the rate specified for that date in the related terms document.

Section 1.02.          Governing Law; Submission to Jurisdiction; Agent for Service of Process.  This Terms Document shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to principles of conflict of laws.  The parties hereto declare that it is their intention that this Terms Document shall be regarded as made under the laws of the State of Delaware and that the laws of said State shall be applied in interpreting its provisions in all cases where legal interpretation shall be required.  Each of the parties hereto agrees (a) that this Terms Document involves at least $100,000.00, and (b) that this Terms Document has been entered into by the parties hereto in express reliance upon 6 DEL. C. § 2708.  Each of the parties hereto hereby irrevocably and unconditionally agrees (a) to be subject to the jurisdiction of the courts of the State of Delaware and of the federal courts sitting in the State of Delaware, and (b)(1) to the extent such party is not otherwise subject to service of process in the State of Delaware, to appoint and maintain an agent in the State of Delaware as such party’s agent for acceptance of legal process, and (2) that, to the fullest extent permitted by applicable law, service of process may also be made on such party by prepaid certified mail with a proof of mailing receipt validated by the United States Postal Service constituting evidence of valid service, and that service made pursuant to (b)(1) or (2) above shall, to the fullest extent permitted by applicable law, have the same legal force and effect as if served upon such party personally within the State of Delaware.

 

- 5 -

Section 1.03.          Counterparts.  This Terms Document may be executed in any number of counterparts, each of which so executed will be deemed to be an original, but all such counterparts will together constitute but one and the same instrument.

Section 1.04.          Ratification of Indenture and Indenture Supplement.  As supplemented by this Terms Document, each of the Indenture and the Indenture Supplement is in all respects ratified and confirmed and the Indenture as so supplemented by the Indenture Supplement as so supplemented and this Terms Document shall be read, taken and construed as one and the same instrument.

[END OF ARTICLE I]

 

- 6 -

ARTICLE II

The Class A(2018‐2) Notes

Section 2.01.         Creation and Designation.  There is hereby created a tranche of BAseries Class A Notes to be issued pursuant to the Indenture and the Indenture Supplement to be known as the “BAseries Class A(2018‐2) Notes.”

Section 2.02.          Specification of Required Subordinated Amount and other Terms.

(a)        For the Class A(2018‐2) Notes for any date of determination, the Class A Required Subordinated Amount of Class B Notes will be an amount equal to 14.28571% of (i) the Adjusted Outstanding Dollar Principal Amount of the Class A(2018‐2) Notes on such date or (ii) if an Early Redemption Event with respect to the Class A(2018‐2) Notes shall have occurred, if an Event of Default and acceleration of the Class A(2018‐2) Notes shall have occurred or if the Class A Usage of the Class B Required Subordinated Amount for such tranche of Class A Notes is greater than zero, the Adjusted Outstanding Dollar Principal Amount of the Class A(2018‐2) Notes as of close of business on the day immediately preceding the occurrence of such Early Redemption Event, such Event of Default and acceleration or the date on which the Class A Usage of Class B Required Subordinated Amount exceeded zero.

(b)       For the Class A(2018‐2) Notes for any date of determination, the Class A Required Subordinated Amount of Class C Notes will be an amount equal to 12.69841% of (i) the Adjusted Outstanding Dollar Principal Amount of the Class A(2018‐2) Notes on such date or (ii) if an Early Redemption Event with respect to the Class A(2018‐2) Notes shall have occurred, if an Event of Default and acceleration of the Class A(2018‐2) Notes shall have occurred or if the Class A Usage of the Class C Required Subordinated Amount for such tranche of Class A Notes is greater than zero, the Adjusted Outstanding Dollar Principal Amount of the Class A(2018‐2) Notes as of close of business on the day immediately preceding the occurrence of such Early Redemption Event, such Event of Default and acceleration or the date on which the Class A Usage of Class C Required Subordinated Amount exceeded zero.

(c)        The Issuer may change the percentages set forth in clause (a) or (b) above without the consent of any Noteholder so long as the Issuer has (i) received written confirmation from each Note Rating Agency that has rated any Outstanding Notes of the BAseries that the change in either of such percentages will not result in a Ratings Effect with respect to any Outstanding Notes of the BAseries and (ii) delivered to the Indenture Trustee and the Note Rating Agencies a Master Trust Tax Opinion and an Issuer Tax Opinion. 

Section 2.03.          Interest Payment.

(a)       For each Interest Payment Date (other than the first Interest Payment Date), the amount of interest due with respect to the Class A(2018‐2) Notes shall be an amount equal to one-twelfth of the product of (i) the Note Interest Rate times (ii) the Outstanding Dollar Principal Amount of the Class A(2018‐2) Notes determined as of the Record Date preceding the related Transfer Date; provided, however, that for the first Interest Payment Date the amount of interest due is $5,800,000.  Interest on the Class A(2018‐2) Notes will be calculated on the basis of a 360-day year consisting of twelve 30-day months.

 

- 7 -

(b)       Pursuant to Section 3.03 of the Indenture Supplement, on each Transfer Date, the Indenture Trustee shall deposit into the Class A(2018‐2) Interest Funding sub-Account the portion of BAseries Available Funds allocable to the Class A(2018‐2) Notes. 

Section 2.04.         Payments of Interest and Principal.  Any installment of interest or principal, if any, payable on any Class A(2018‐2) Note which is punctually paid or duly provided for by the Issuer and the Indenture Trustee on the applicable Interest Payment Date or Principal Payment Date shall be paid by the Paying Agent to the Person in whose name such Class A(2018‐2) Note (or one or more Predecessor Notes) is registered on the Record Date, by wire transfer of immediately available funds to such Person’s account as has been designated by written instructions received by the Paying Agent from such Person not later than the close of business on the third Business Day preceding the date of payment or, if no such account has been so designated, by check mailed first-class, postage prepaid to such Person’s address as it appears on the Note Register on such Record Date, except that with respect to Notes registered on the Record Date in the name of the nominee of Cede & Co., payment shall be made by wire transfer in immediately available funds to the account designated by such nominee.

The right of the Class A(2018‐2) Noteholders to receive payments from the Issuer will terminate on the first Business Day following the Class A(2018‐2) Termination Date.

Section 2.05.          Form of Delivery of Class A(2018‐2) Notes; Depository; Denominations.

(a)        The Class A(2018‐2) Notes shall be delivered in the form of a global Registered Note as provided in Sections 202 and 301(i) of the Indenture, respectively.

(b)        The Depository for the Class A(2018‐2) Notes shall be The Depository Trust Company, and the Class A(2018‐2) Notes shall initially be registered in the name of Cede & Co., its nominee.

(c)        The Class A(2018‐2) Notes will be issued in minimum denominations of $5,000 and multiples of $1,000 in excess of that amount.

Section 2.06.          Delivery and Payment for the Class A(2018‐2) Notes.  The Issuer shall execute and deliver the Class A(2018‐2) Notes to the Indenture Trustee for authentication, and the Indenture Trustee shall deliver the Class A(2018‐2) Notes when authenticated, each in accordance with Section 303 of the Indenture.

Section 2.07.          Targeted Deposits to the Accumulation Reserve Account.  The deposit targeted to be made to the Accumulation Reserve Account for any Monthly Period during the Accumulation Reserve Funding Period will be an amount equal to the Required Accumulation Reserve sub-Account Amount.

[END OF ARTICLE II]

 

- 8 -

ARTICLE III

Representations and Warranties

Section 3.01.         Issuer’s Representations and Warranties.  The Issuer makes the following representations and warranties as to the Collateral Certificate on which the Indenture Trustee is deemed to have relied in acquiring the Collateral Certificate.  Such representations and warranties speak as of the execution and delivery of this Terms Document, but shall survive until the termination of this Terms Document.  Such representations and warranties shall not be waived by any of the parties to this Terms Document unless the Issuer has obtained written confirmation from each Note Rating Agency that there will be no Ratings Effect with respect to such waiver.

(a)       The Indenture creates a valid and continuing security interest (as defined in the Delaware UCC) in the Collateral Certificate in favor of the Indenture Trustee, which security interest is prior to all other liens, and is enforceable as such as against creditors of and purchasers from the Issuer.

(b)       The Collateral Certificate constitutes either an “account,” a “general intangible,” an “instrument,” or a “certificated security,” each within the meaning of the Delaware UCC.

(c)       At the time of the transfer and assignment of the Collateral Certificate to the Indenture Trustee pursuant to the Indenture, the Issuer owned and had good and marketable title to the Collateral Certificate free and clear of any lien, claim or encumbrance of any Person.

(d)       The Issuer has caused, within ten days of the execution of the Indenture, the filing of all appropriate financing statements in the proper filing office in the appropriate jurisdictions under applicable law in order to perfect the security interest in the Collateral Certificate granted to the Indenture Trustee pursuant to the Indenture.

(e)       Other than the security interest granted to the Indenture Trustee pursuant to the Indenture, the Issuer has not pledged, assigned, sold, granted a security interest in, or otherwise conveyed the Collateral Certificate.  The Issuer has not authorized the filing of and is not aware of any financing statements against the Issuer that include a description of collateral covering the Collateral Certificate other than any financing statement relating to the security interest granted to the Indenture Trustee pursuant to the Indenture or any financing statement that has been terminated.  The Issuer is not aware of any judgment or tax lien filings against the Issuer.

(f)        All original executed copies of the Collateral Certificate have been delivered to the Indenture Trustee.

(g)       At the time of the transfer and assignment of the Collateral Certificate to the Indenture Trustee pursuant to the Indenture, the Collateral Certificate had no marks or notations indicating that it has been pledged, assigned or otherwise conveyed to any Person other than the Indenture Trustee.

[END OF ARTICLE III]

 

- 9 -

IN WITNESS WHEREOF, the parties hereto have caused this Terms Document to be duly executed, all as of the day and year first above written.

	   	
BA CREDIT CARD TRUST,

by BA CREDIT CARD FUNDING, LLC,

as Beneficiary and not in its individual capacity

	 	 	 
	 	
By:

	
 

	 	 	
Name:  

	 	 	
Title:  

 

[Signature Page to the Class A(2018‐2) Terms Document]

 

	  	
THE BANK OF NEW YORK MELLON, as Indenture Trustee

and not in its individual capacity

	 	 	 
	 	
By:

	
 

	 	 	
Name:  

	 	 	
Title:  

 

[Signature Page to the Class A(2018‐2) Terms Document]EX-10.10

 Exhibit 10.10 

Confidential Treatment Requested by MeiraGTx Holdings plc 
  

 LICENSE AGREEMENT 

between 
 BRANDEIS
UNIVERSITY 
 and 

BRI-Alzan Inc. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 LICENSE AGREEMENT 

This License Agreement (“Agreement”), effective as of May 1, 2013 (“Effective Date”) between Brandeis University, a not-for-profit corporation duly organized and existing under the laws of The Commonwealth of Massachusetts and having its principal place of business at 415 South Street,
Waltham, Massachusetts 02454-9110 (“Brandeis”), and BRI-Alzan Inc., a corporation duly organized and existing under the laws of the State of Delaware and having offices at c/o Fidelity Biosciences Corp., One Main Street, 13th Floor,
Cambridge, MA 02142 (hereinafter referred to as “Licensee”). 
 WHEREAS, Brandeis through research conducted by Dagmar Ringe,
Gregory Petsko and Xu Simon (the “Inventors”), has developed an invention pertaining to by Brandeis Case No. 1092 “Protein Therapy for ALS”, for which Brandeis has filed patent applications. 

WHEREAS, as a center for research and education, Brandeis desires to license the Patent Rights and thus benefit the public and Brandeis by
facilitating the dissemination of the results of its research in the form of useful products. However, Brandeis itself does not have the capacity to commercially develop, manufacture or distribute the Licensed Products, and is therefore willing to
grant an exclusive license to the Licensee in the technology. 
 WHEREAS, Licensee having such capacity, desires to commercially develop,
manufacture, use and distribute such Licensed Products. 
 WHEREAS, Brandeis and Fidelity Biosciences Corp, (as defined herein) have entered
into a Research Agreement (as defined herein) and Brandeis and Fidelity Biosciences Corp, have acknowledged that this Agreement is an Alternative Arrangement (as defined in the Research Agreement), which shall be in lieu of and not in addition to
the license set forth in the Research Agreement. 
 NOW THEREFORE, in consideration of the mutual covenants of this Agreement, the parties
agree: 
 1. DEFINITIONS 

1.1 “Accounting Period” means each three month period during the term of this Agreement, including partial periods at the beginning
and end of the term of this Agreement, ending March 31, June 30, September 30 and December 31. 
 1.2 “Affiliate”
means, with respect to any specified Person, any other Person who, directly or indirectly, Controls, is Controlled by, or is under common Control with such Person, including without limitation any entity that is a general partner or managing member
of such Person. The term “Control” of a given Person means possession, direct or indirect, of the power to direct the management or policies of such Person, directly or indirectly, whether through the ownership of voting securities, by
contract or otherwise, and the terms “Controlling” and “Controlled” shall have meanings correlative to the foregoing. 

1.3 [Reserved] 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 1.4 “Change of Control” means transfer of all, or substantially all, of the rights
granted in the Agreement to a non-Affiliate assignee, in accordance with Section 10.4, hereunder, or to a Sublicensee in accordance with Section 2.2, hereunder. 

1.5 “Fidelity Biosciences” means Fidelity Biosciences Corp. (“FBC”), a Delaware corporation. 

1.6 “First Commercial Sale” means the first sale of any Licensed Product by Licensee or its Affiliates or its Sublicensees (each, a
“Seller”). 
 1.7 “Gross Sales” or “Gross Sales Price” means for any arm’s length sale, transfer,
dispositions or other dealing to a customer by a Seller, the Gross Sales Price shall be the gross amount invoiced by the Seller for the sale, transfer or other disposition of or dealing with a Licensed Product. 

Transfer of a Licensed Product within the Licensee or between Licensee, Sublicensee or an Affiliate shall not be considered a sale, commercial
use or disposition for the purpose of the foregoing paragraphs; in the case of such transfer the Gross Sales Price shall be based on sale of the Licensed Product by the transferee. If a Seller commercially uses or disposes of any Licensed Product by
itself other than in an arm’s length sale to a bona fide customer, the Gross Sales Price hereunder shall be the price which would be then payable in an arm’s length transaction. [***]. 

For any sale of a Licensed Product to which the United States government is entitled to a royalty-free right pursuant to 35 USC 202(c)(paragraph 4), [***].

 1.8 “Know-How” means Brandeis’ rights in discoveries, data (including research, pre-clinical and clinical data), designs, formulas, methods, techniques, materials, technology, results, analyses, and process information (including scientific and technical information) or know-how during the term of this Agreement that are not claimed by the Patent Rights but are, or could reasonably be, necessary for practicing the Patent Rights. 

1.9 “License Fields” mean all fields. 

1.10 “Licensed Products” mean any composition or method, the practice, development, manufacture, use, offer for sale or sale of
which, in whole or in part absent the licenses granted herein, would infringe a Valid Claim of any Patent Right. 
 1.11 “NDA
Filing” means filing a New Drug Application with the USFDA for a Licensed Product. 
 1.12 “Net Sales” or “Net Sales
Price” means the Gross Sales Price received by a Seller less (to the extent appropriately documented) the following amounts actually paid out by a Seller or credited against the amounts received by it from the sale or distribution of Licensed
Product: 
 (a) credits, allowances and price adjustments for damaged Licensed Products or for the rejection or return of Licensed Products
previously sold; 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

2 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 (b) rebates, chargeback payments and trade, cash and quantity discounts to purchasers allowed
and taken; 
 (c) amounts for transportation, insurance, handling or shipping charges directly related to the sale or distribution of
Licensed Product and listed on the invoices or purchase order for such Licensed Product; and 
 (d) taxes, tariffs, duties and other
governmental charges levied on or measured by the sale of Licensed Products, whether absorbed by the Seller or paid by the purchaser so long as the Seller’s price is reduced thereby, but not franchise or income taxes of any kind whatsoever.

 1.13 “Patent Right” means Brandeis’ rights in patents and patent applications listed in Exhibit B, (the
“Applications”), or the equivalent of such Applications, including any division, continuation or any foreign patent application; and any Letters Patent or the foreign equivalent issuing on such applications, and any reexamination or
extension thereof. Patent Rights shall also include those claims in any continuation-in-part application that are supported or enabled by the Applications. All of the
Inventors’ rights, title and interest in the Applications have been assigned to Brandeis. 
 1.14 “Person” means any
corporation, partnership, trust, or limited liability company, association or other entity. 
 1.15 “Phase II Initiation” means the
first dosing of a human subject, in Phase II (Phase Two) Clinical Trials, with a Licensed Product. 
 1.16 “Phase III Initiation”
means the first dosing of a human subject, in Phase III (Phase Three) Clinical Trials, with a Licensed Product. 
 1.17 “Research
Agreement” means the Research Agreement between Brandeis and Fidelity Biosciences, dated as of December 21, 2011. 
 1.18
“Research Agreement Term” means the effective term of the Research Agreement. 
 1.19 “Seller” has the meaning set forth
in Section 1.6. 
 1.20 “Sublicensee” means any non-Affiliate third party licensed by
Licensee or an Affiliate in accordance with Section 2.2 to develop, commercialize, make, have made, use, lease, import, sell or offer for sale any Licensed Product. 

1.21 “Territory” shall mean world-wide. 

1.22 “Valid Claim” means any claim of any Patent Right that has not been (i) finally rejected or (ii) declared invalid by a
patent office or court of competent jurisdiction in any unappealed and unappealable decision. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

3 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 2. LICENSE 

2.1 Grant of License. To the extent not prohibited by the United States Government or by contractual obligations to any other
sponsor of research at Brandeis, and expressly subject to Sections 2.3 through 2.6 below as well as the other terms and conditions of this Agreement, Brandeis hereby grants Licensee: 

2.1.1 an exclusive, terminable, royalty-bearing license under Patent Rights to develop, commercialize, make, have made, use, lease,
import, sell and offer for sale Licensed Products solely in the License Fields in the Territory; and 
 2.1.2 A non-exclusive, terminable, royalty-free license to use the Know-How, solely to the extent necessary to practice the exclusive rights under Section 2.1.1, above. 

All licenses pursuant to this Section 2.1 are subject to the rights, conditions and limitations imposed by U.S. law with respect to
inventions made in the performance of federally funded research. 
 2.2 Right to Sublicense. Brandeis grants to Licensee the
right to grant sublicenses in its rights, privileges and license granted to Licensee in Section 2.1, only with the prior written approval of Brandeis, which permission shall not be unreasonably withheld. 

2.2.1 Sublicenses granted under this Section shall contain all of the conditions, restrictions and reservations of this Agreement,
except for the provisions related to fees and royalties, and must preserve the rights of Brandeis and the U.S. Government existing under this Agreement. Licensee shall promptly provide to Brandeis a copy of any and all fully executed sublicense
agreements, and shall provide to Brandeis, within [***] ([***]) days of the end of each Accounting Period, a copy of reports received by Licensee from its Sublicensees for the previous Accounting Period relating to royalty or non-royalty consideration under such sublicense agreements. 
 2.2.2 [***]. 

2.2.3 The granting of a sublicense by Licensee shall not operate to relieve Licensee from any of its obligations under this Agreement.
Licensee shall be responsible for and remit royalties based upon its Sublicensee’s activities as if said activities were its own. 

2.3 Reservation of Rights. Brandeis expressly reserves the right to make, have made and to use and transfer the subject matter
described and claimed in the Patent Rights for any noncommercial purpose. 
 2.4 [***] Manufacturing. Licensee agrees that
[***]. 
 2.5 Scope. Nothing herein shall be construed to grant Licensee a license, express or implied, under any intellectual
property right owned solely or jointly by Brandeis other than the Patent Rights and Know-How expressly licensed hereunder. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

4 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 2.6 Affiliates. Licensee may extend the license granted herein to any Affiliate
of Licensee if the Affiliate consents in writing to be bound by this Agreement to the same extent as Licensee. Licensee must deliver to Brandeis a true and accurate copy of such written agreement, and any modification or termination thereof, within
[***] days after execution, modification or termination. 
 2.7 Liability. Notwithstanding any liability that may accrue
directly to any Affiliate or Sublicensee hereunder, Licensee shall remain directly liable to Brandeis for any amount due from or liability incurred or accrued by any Sublicensee or Affiliate under this Agreement. 

2.8 Representation. Brandeis represents, to the best of its knowledge, that all of the Inventors’ rights, title and interest
in the Applications have been assigned to Brandeis. Licensee acknowledges receipt of copies of the patent assignments from Brandeis. 

3. DILIGENCE OBLIGATIONS 

3.1 Commercialization Milestones. Licensee shall itself, or through its Affiliates or Sublicensees, use commercially reasonable
efforts to develop Licensed Products for commercial sales and distribution in the License Fields in the Territory and to continue active, diligent marketing efforts for Licensed Products throughout the life of this Agreement. Such efforts require
achieving the following objectives: 
 (a) During the last [***] ([***]) months of the Research Agreement Term, the parties will meet and
mutually agree on due dates for the following milestones. These milestone due dates shall be incorporated into this agreement: 
  

			
		
	 Milestone
	  	 Achievement Due Date (to be added in accordance with this Section 3.1(a)

		
	 (i) Phase II Initiation
	  	
		
	 (ii) Phase III Initiation
	  	
		
	 (iii) NDA Filing
	  	

 If Licensee fails to achieve one or more of the above objectives within the above stated periods, Brandeis, in
its sole discretion, shall have the right to terminate any exclusive or nonexclusive license granted hereunder in accordance with Section 9.2.1, below. 

3.2 Progress Reports. Within [***] ([***]) days of the end of its fiscal year, Licensee shall provide a written report to
Brandeis detailing its progress or lack of progress, along with supporting documentation, made toward the foregoing objectives. 
 3.3
Research Agreement. The parties acknowledge that the Research Agreement was signed December 21, 2011, and that FBC has paid all fees due under the Research Agreement to date. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

5 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 4. PAYMENTS AND REPORTS 

4.1 Fees and Royalties. In consideration for the rights, privileges and license granted under this Agreement, Licensee shall pay
to Brandeis the fees, equity and royalties set forth in Exhibit A. In each year the amount of royalty and sublicense fees due shall be calculated quarterly as of the end of each Accounting Period and shall be paid within [***] ([***]) days following
the end of such Accounting Period. 
 4.2 Late Payments. If any payment due under this Agreement is not paid within [***]
([***]) days of the date upon which such payment is due, then interest shall accrue on such payment on a daily basis from the date such payment was originally due at a rate equal to [***] ([***]) month LIBOR (as published in The Wall Street Journal,
New York edition) plus [***] percent ([***]%) per annum, calculated daily, or at the maximum rate permitted by law, whichever is the lower, and such interest shall be paid when such payment is made. The payment of such interest shall not preclude
the party receiving such interest from exercising any other rights it may have as a consequence of the lateness of any payment. 
 4.3
Conversion. All amounts payable by Licensee must be paid in United States dollars without deductions for taxes, assessments, fees, or charges of any kind. Royalties accruing on sales in countries other than the United States must be paid in
United States dollars in amounts based on the rate of exchange as quoted in the Wall Street Journal (WSJ) as of the last business day of the reporting period. If the WSJ does not publish any such rate, a comparable rate publication will be agreed
upon from time to time by the parties, and with respect to each country for which such rate is not published by the WSJ or in a comparable publication, the parties will use the prevailing rate for bank cable transfers for such date, as quoted by
leading United States banks in Boston dealing in the foreign exchange market. 
 4.4 Records. Licensee shall keep complete and
accurate records of its, and its Affiliates and Sublicensees’ Net Sales under the license granted in this Agreement in sufficient detail to enable the royalties payable hereunder to be determined. Such records shall be retained for at least
[***] ([***]) years following the end of the Accounting Period to which such records relate. Licensee agrees to permit Brandeis or its representatives, at Brandeis’ expense and with [***] days written notice, to periodically examine its
books, ledgers, and records during regular business hours for the purpose of and to the extent necessary to verify any report and payment required under this Agreement. If the amounts due to Brandeis are determined to have been underpaid, by [***]
percent ([***]%) or more, Licensee will pay the cost of the examination and all overdue amounts with accrued interest in accordance with Section 4.2. 

4.5 Royalty Reports. Whether or not a payment is due, Licensee shall deliver to Brandeis a full and accurate reporting and
accounting, certified as such by an officer of Licensee, as well as supporting documents as required by Sections 2.2, 2.6 and 3.2 and this Section 4.5 regarding any royalties or other consideration, and shall include at least the following
information for the preceding Accounting Period within [***] ([***]) days of the end of the preceding Accounting Period: 
 4.5.1
Quantity of each Licensed Product sold (by country) by the Sellers; 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

6 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 4.5.2 Total billings for each Licensed Product (by country); 

4.5.3 Quantities of each Licensed Product used by Licensee and its Affiliates or Sublicensees; 

4.5.4 An accounting of all deductions applicable to determine the Net Sales; 

4.5.5 Names and addresses of all Sublicensees and Affiliates subject to Section 2.6 of Licensee; and 

4.5.6 Total royalties payable to Brandeis. 

4.6 Annual Reports. Licensee shall deliver to Brandeis a copy of its financial statements, certified by an officer of Licensee,
and evidence or renewal of insurance in accordance with Section 7.2, below, within [***] ([***]) days of the end of its fiscal year. Licensee shall deliver to Brandeis its annual reports to stock holders and material revisions to its business
plan when prepared. 
 4.7 Delivery. All payments and reports due Brandeis shall be made payable to Brandeis University, shall
include documentation as described in this Section 4 and reference to Brandeis Reference # 1092, and delivered to: 
 Director, Office
of Technology Licensing 
 Brandeis University, MS115 

415 South Street 
 Waltham, MA
02454-9110 
 5. FILING, PROSECUTION AND MAINTENANCE OF PATIENT RIGHT 

5.1 Responsibility; Costs. Brandeis shall be responsible for the searching, preparation, filing, prosecution and maintenance of
all patent applications and patents included in Patent Rights. Brandeis retains the right to select the attorney responsible for the prosecution and maintenance of the Patent Rights and to present such attorney to Licensee for Licensee’s
approval which shall not be unreasonably withheld or delayed. The attorney responsible for the prosecution and maintenance of the Patent Rights shall be retained by mutual agreement of Brandeis and Licensee. Brandeis or its attorneys shall consult
with Licensee with respect to all proposed actions and filings described in this Section 5.1 and shall provide Licensee with reasonable opportunities to advise Brandeis concerning the same. Licensee shall take reasonable actions to cooperate
with Brandeis in such filing, prosecution and maintenance. Licensee shall reimburse Brandeis for all reasonable costs incurred by Brandeis for the preparation, filing, prosecution and maintenance of all Patent Rights (“Costs”) as follows:

 5.1.1 Subject to paragraph 5.1, above, for all Costs incurred by Brandeis prior to and after the Effective Date, Licensee shall
reimburse Brandeis within [***] ([***]) days of receipt of invoices from Brandeis. Brandeis shall prepare, file, prosecute, and maintain all of the licensed Patent Rights. Brandeis and its appointed patent attorneys will [***] copy Licensee on all
patent correspondence as follows: (a) documents received from any patent office shall be provided to Licensee promptly after receipt; (b) any document to be filed in any patent office 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

7 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
shall be provided in draft form to Licensee sufficiently prior to such document’s filing to allow for review and comment by Licensee; and (c) documents filed with any patent office
shall be provided to Licensee promptly after filing. Licensee shall have reasonable opportunities to advise Brandeis and shall cooperate with Brandeis in such filing, prosecution and maintenance. Brandeis will cooperate with Licensee to manage
patent costs. 
 6. INFRINGEMENT 

6.1 Notice. If Licensee becomes aware of any actual, potential, or threatened infringement, misappropriation, act of unfair
competition, or other harmful or wrongful activities of third parties with respect to the Patent Rights, Licensee shall, with reasonable promptness, notify Brandeis and provide relevant information and documentation. Licensee will not notify a third
party of the infringement of any Patent Rights without first obtaining consent of Brandeis. 
 6.2 Enforcement by Licensee. So
long as Licensee remains the exclusive licensee of the Patent Rights in the License Fields in the Territory, Licensee, to the extent permitted by law, shall have the right, under its own control and at its own expense, to prosecute any third party
infringement of the Patent Rights in the License Fields in the Territory, subject to Sections 6.2.1 and 6.2.2, below. If required by law, Brandeis shall permit any action under this Section to be brought in its name, including being joined as a
party-plaintiff, provided that Licensee shall hold Brandeis harmless from, and indemnify Brandeis against, any costs, expense or liability that Brandeis incurs in connection with such action; provided that Licensee shall not be obligated to
indemnify Brandeis against any liability under this Section 6.2 that Brandeis incurs as a result of its own gross negligence or willful misconduct as determined by a court of final adjudication after exhaustion of all available appeals. 

Prior to commencing any action, Licensee shall consult with Brandeis and shall consider the views of Brandeis regarding the advisability of the
proposed action and its effect on the public interest. Licensee shall not enter into any settlement, consent, judgment or other voluntary final disposition of any infringement action under this Section without the prior written consent of Brandeis.

 6.2.1 Payment of Royalties. If Licensee brings an action under this Section 6.2, Licensee may deduct from its royalty
payments due to Brandeis pursuant to Exhibit A.1, an amount not to exceed [***] percent ([***]%) of Licensee’s documented and actually paid or currently outstanding, costs and expenses of such action, including reasonable attorneys’
fees, up to a total of [***] percent ([***]%) of the total royalty due to Brandeis in any Accounting Period. 
 6.2.2 Treatment of
Proceeds. Any recovery or damages for past infringement derived therefrom or any amounts paid as a result of a settlement agreement (the “Gross Proceeds”) shall be applied first in satisfaction of any unreimbursed expenses and
reasonable legal fees of the parties,. [***]. 
 6.3 Enforcement by Brandeis. In the event that Licensee is unsuccessful in
persuading the alleged infringer to desist or fails to have initiated an infringement action within [***] ([***]) months after Licensee first becomes aware of the basis for such action, Brandeis shall have the right, at its sole discretion, to
prosecute such infringement under its sole control and at its sole expense, and any recovery obtained shall belong to Brandeis. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

8 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 6.4 Actions for Declaratory Judgment. If a declaratory judgment action alleging
invalidity or infringement of any of the Patent Rights is brought against Licensee, Brandeis, within [***] ([***]) days of being notified of such action, in its sole discretion, shall have the right (but not the obligation) to intervene and take
over the sole defense of the action at its own expense. Licensee shall cooperate fully with Brandeis in connection with any such action. Any recovery of damages by Brandeis shall be applied first in satisfaction of any unreimbursed expenses of both
Brandeis and Licensee. If Brandeis elects not to intervene, Licensee may assume the defense and may escrow royalties, otherwise due Brandeis pursuant to Section 6.2.1 and apportion damages in the same proportions and to the same extent as set
forth in Section 6.2.2 hereof. [***]. 
 6.5 Cooperation. In any infringement suit as either party may institute to
enforce Patent Rights or in any defense of Patent Rights pursuant to this Agreement, the other party hereto shall, at the request and expense of the party initiating such suit, cooperate in all respects to the extent reasonably possible. 

6.6 Non-Assert. Notwithstanding other provisions of this Article 6, Licensee
(including its Affiliates and Sublicensees) and Brandeis agree that the Patent Rights shall not be asserted against not-for-profit research institutions for use on
research funded by the institutions themselves, by not-for-profit foundations, by the Howard Hughes Medical Institute, by any state government, or by the Federal
Government. Licensee may assert the Patent Rights [***], and may assert the Patent Rights [***]. 
 6.7 Survival. The
provisions of this Section 6 shall survive any termination of this Agreement but only in respect of proceedings commenced prior to the date of termination for alleged or actual acts of infringements occurring during the term of this Agreement.

 7. INDEMNIFICATION; INSURANCE 

7.1 By Licensee. Licensee shall indemnify, defend and hold harmless Brandeis, and its current or former trustees, officers,
governing board members, faculty, professional staff, employees, students, agents and Affiliates, and their respective successors, heirs and assigns (collectively, “Indemnitees”), against any and all liability, damage, loss, claim or
expense (including legal expenses and reasonable attorneys’ fees) incurred by or imposed upon the Indemnitees or any one of them in connection with any claims, suits, actions, demands or judgments arising out of or in connection with the
transport, handling, research, development, design, manufacture, commercialization, marketing, sale, use, lease, consumption or advertisement of Licensed Products, including any actual or alleged injury, damage, death or other consequence occurring
to any persons or property, and including against any claim that activities under this License Agreement infringe a third party’s intellectual property rights, and against any other claim, proceeding, demand, expense and liability of any kind
whatsoever (including, without limitation, actions in the form of tort warranty, or strict liability) resulting, directly or indirectly, from the possession, use or consumption of any Licensed Products or arising from any obligation of Licensee
hereunder; provided that Licensee shall not be obligated 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

9 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
to indemnify the Indemnitees against any liability under this Section 7.1 that the Indemnitees incur as a result of their own gross negligence or willful misconduct as determined by a court
of final adjudication after exhaustion of all available appeals. Licensee shall, at its own expense, provide attorneys reasonably acceptable to Brandeis to defend against any actions brought or filed against any Indemnitee hereunder with respect to
the subject of indemnity contained herein, whether or not such actions are rightfully brought. 
 7.2 Insurance. Prior to first
dosing of humans in a Phase I clinical trial with Licensed Product, Licensee shall, at its sole cost and expense, procure and maintain, or cause to be maintained (i) commercial general liability insurance, on an occurrence basis, in amounts not
less than $[***] per occurrence and $[***] annual aggregate and, (ii) product liability insurance in amounts not less than $[***] per claim and $[***] annual aggregate. Such insurance policies shall (i) be through an insurance company with
an A.M. Best minimum rating of [***]; (ii) name the Indemnitees as additional insureds; (iii) [***]; and (iv) [***]. The minimum amounts of insurance coverage required under this Section 7.2 shall not be construed to create a limit of
Licensee’s liability with respect to its indemnification under Section 7.1. 
 7.2.1 Licensee shall provide Brandeis with an
acceptable certificate as written evidence of such insurance prior to the use in humans of any Licensed Product. Licensee shall provide Brandeis with written notice at least [***] ([***]) days prior to the cancellation, nonrenewal or material
reduction in such insurance; if Licensee does not obtain replacement insurance providing comparable coverage prior to the expiration of such [***] ([***]) day period, Brandeis shall have the right to terminate this Agreement effective at the end of
such [***] ([***]) day period without notice or any additional waiting periods. 
 7.2.2 Licensee shall maintain such insurance beyond
the expiration or termination of this Agreement during (i) the period that any such Licensed Product, process, or service is being commercially distributed or sold by any Seller and (ii) a reasonable period after the period referred to in
(i) but in no event less than [***]. 
 7.3 IN NO EVENT SHALL BRANDEIS BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL OR
CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR EXPECTED SAVINGS OR OTHER ECONOMIC LOSSES, OR FOR INJURY TO PERSONS OR PROPERTY) ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER,
REGARDLESS OF WHETHER BRANDEIS KNOWS OR SHOULD KNOW OF THE POSSIBILITY OF SUCH DAMAGES. BRANDEIS’ AGGREGATE LIABILITY FOR ALL DAMAGES OF ANY KIND RELATING TO THIS AGREEMENT OR ITS SUBJECT MATTER SHALL NOT EXCEED THE AMOUNT PAID BY LICENSEE TO
BRANDEIS UNDER THIS AGREEMENT. The foregoing exclusions and limitations shall apply to all claims and actions of any kind, whether based on contract, tort (including but not limited to negligence), or any other grounds. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

10 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 8. DISCLAIMER 

BRANDEIS MAKES NO WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR ANY IMPLIED WARRANTY
OF FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY PATENT, TRADE SECRET, TANGIBLE RESEARCH PROPERTY, TECHNOLOGY, INFORMATION, KNOW-HOW OR DATA LICENSED OR OTHERWISE PROVIDED TO LICENSEE HEREUNDER AND
HEREBY DISCLAIMS THE SAME. THE PATENT RIGHTS AND KNOW-HOW ARE PROVIDED AS IS. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY BRANDEIS THAT THE PRACTICE BY LICENSEE
OR THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY. 
 Licensee understands and acknowledges that
Brandeis, by this Agreement, makes no representation as to the operability or fitness for any use, safety, efficacy, approvability by regulatory authorities, time and cost of development, patentability, and/or breadth of the Patent Rights, by this
Agreement. Brandeis also makes no representation as to whether there are any patents now held, or which will be held, by others or by Brandeis which may be dominant or subordinate to Patent Rights. 

9. TERMINATION 
 9.1
Term. Unless sooner terminated as provided for in this Agreement, the license to Patent Rights granted hereunder will be effective upon the Effective Date and will continue on a country by country basis until the first to occur: 

(a) one (1) year after the date Licensee, its Affiliates, or Sublicensees shall last sell any Licensed Product in such country; or 

(b) until the last to expire of any Patent Right, the claims of which but for this Agreement would be infringed by the manufacture, use or sale
of any Licensed Product in the applicable country. 
 9.2 Termination. 

9.2.1 Breach. If Licensee breaches any of its financial obligations under this Agreement, Brandeis may give written notice of the
default to Licensee. Unless such default is corrected within thirty (30) days after such notice, Brandeis may immediately terminate this Agreement and the license hereunder without any additional notice. Only one such thirty (30) day grace
period shall be available in any twelve (12) month period with respect to a default of any particular financial provision hereunder. Thereafter notice of default of such provision shall constitute immediate termination. If Licensee materially
breaches any of its obligations, other than the financial obligations specified above in this paragraph, Brandeis may give written notice of the default to Licensee. Unless such default is corrected within sixty (60) days after such notice,
Brandeis may immediately terminate this Agreement and the license hereunder without any additional notice. Only one such sixty (60) day grace period shall be available in any twelve (12) month period with respect to a default of any
particular non-financial provision hereunder. Thereafter notice of default of such provision shall constitute immediate termination. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

11 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 9.2.2 Bankruptcy. Licensee must provide notice to Brandeis of its intention to
file a voluntary petition in bankruptcy or, where known to Licensee, of another party’s intention to file an involuntary petition in bankruptcy for Licensee, within at least thirty (30) days prior to filing such petition. Brandeis may
terminate this Agreement upon receipt of such notice at its sole discretion. Licensee’s failure to provide such notice to the University will be deemed a material, pre-petition, incurable breach of this
Agreement and the Agreement will terminate automatically on the date of filing such voluntary or involuntary petition in bankruptcy. 

9.3 Effect of Termination. 

9.3.1 Sublicenses. Upon any termination, all licenses granted to Licensee and Affiliates under this Agreement are terminated,
however, any sublicense under such license granted prior to termination shall remain in full force and effect, provided that: 
 (a) Brandeis
receives all payments due hereunder; and 
 (b) the Sublicensee is not then in breach of its sublicense agreement; and 

(c) the Sublicensee assumes in writing Licensees’ or the applicable Affiliates’ obligations under, and the terms and conditions of
this Agreement; and 
 (d) Brandeis shall have the right to receive the greater of (a) [***] or (b) the lowest royalty which is within
the “Competitive” range as hereinafter defined, at the time Brandeis’ license to Licensee is terminated. A royalty rate shall be regarded as “Competitive” if it is within the range of royalty rates that [***]; and 

(e) Brandeis shall not assume, and shall not be responsible to such Sublicensee for, any representations, warranties or obligations of Licensee
to such Sublicensee, other than to permit such Sublicensee to exercise any rights to Patent Rights that are granted under such sublicense agreement consistent with the terms of this Agreement. 

9.3.2 Obligations. Termination of this Agreement does not relieve Licensee or any Affiliate of any obligation or liability
accrued by Licensee or any Affiliate prior to the effective date of such termination or affect any rights of Brandeis arising under this Agreement prior to termination. Also, upon any termination of this Agreement, whether by Brandeis or by
Licensee, Licensee and its Affiliates shall cease all use of the Patent Rights and Know-How, and shall, upon request, return or destroy (at Brandeis’ option) all tangible embodiments thereof under its
control or in its possession. 
 9.4 Survival. In addition to provisions that expressly provide for survival, Sections 1,
4.4, 6, 7, 8, 9.3, 9.4, and 10.5 survive termination of this Agreement. 
 10. MISCELLANEOUS 

10.1 Relationship of the Parties. The parties to this Agreement are independent contractors. It is expressly agreed that in
exercising its rights granted hereunder, each party is acting as independent contractor and not as agent or employee of the other party, and nothing contained in this Agreement shall be construed to create an agency, joint venture, or partnership
between the parties. Neither party shall have any right, power or authority to enter into any agreement for or on behalf of, or incur any obligation or liability of, or to otherwise bind, the other party. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

12 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 10.2 Use of Names; Publicity. Except as required by law, neither party shall
use the name of the other party or any of their respective officers, employees, students, consultants, Affiliates or agents (or any trade-name, trademark, trade device, service mark, symbol, or any abbreviation, contraction or simulation thereof
owned by the other party or any of their respective officers, employees, students, consultants, Affiliates or agents) in any press release, promotional material or other publicity without the prior written consent of the other party. 

10.3 Notice. Any notices or other communications required or permitted hereunder shall be sufficiently given if delivered
personally, sent by reputable overnight delivery service (such as Federal Express or Airborne Express) or sent by first class certified United States mail, postage prepaid, addressed as follows or to such other address of which the parties may have
given notice: 
 To Brandeis: 

Director 
 Office of Technology
Licensing 
 Brandeis University 

415 South Street, MS 115 

Waltham, Massachusetts 02454-9110 

To Licensee: 
 c/o Fidelity
Biosciences Corp., 
 One Main Street, 13th Floor, 

Cambridge, MA 02142, 
 Attention:
[***] 
 Unless otherwise specified herein, such notices or other communications shall be deemed received (a) on the date delivered, if
delivered personally, (b) one business day after being sent, if sent by reputable overnight delivery service or (c) three business days after being sent, if sent by certified mail. 

10.4 Assignment. This Agreement may not be assigned or otherwise transferred by Licensee without the prior written consent of
Brandeis, such consent not to be unreasonably withheld, delayed or conditioned. Notwithstanding the foregoing, this Agreement may be assigned by Licensee without the consent of Brandeis (a) to an Affiliate , and (b) in connection with the
transfer or sale, directly or indirectly, of all or substantially all of the assets and business of Licensee to a third party, whether by merger, sale of stock, sale of all or substantially all assets, consolidation, recapitalization, or other
business combination, provided that, with respect to (a) and (b) above, (i) Licensee is in good standing, (ii) any such permitted assignee shall assume all obligations of its assignor under this Agreement in writing,
(iii) Licensee or assignee shall deliver a fully executed copy of such assumption of obligations to Brandeis within [***] ([***]) days of completing the assignment, and (iv) [***]. Any purported assignment in violation of this Section shall be
null and void. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

13 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 10.5 Governing Law. This Agreement shall be governed by and construed in
accordance under the laws of The Commonwealth of Massachusetts, without giving effect to its principles of conflict or choice of laws. Each of the parties hereto agree that any action at law or in equity arising out of or relating to this Agreement
shall be filed exclusively in courts of competent jurisdiction located in Boston, Massachusetts. Each party hereby consents to the personal jurisdiction of the courts in The Commonwealth of Massachusetts. 

10.6 Entire Agreement; Amendments. This Agreement and its Exhibits represent the entire understanding and agreement between the
parties hereto with respect to the subject matter hereof and supersede all prior oral and written and all contemporaneous oral negotiations, commitments and understandings between such parties. This Agreement may not be modified or amended except by
a written agreement duly executed by both parties hereto. 
 10.7 Waivers. No delay on the part of any party in exercising any
right, power or privilege hereunder shall operate as a waiver thereof nor shall any waiver on the part of any party of any such right, power or privilege, nor any single or partial exercise of any such right, power or privilege, preclude any further
exercise thereof or the exercise of any other such right, power or privilege. The rights and remedies of any party based upon, arising out of or otherwise in respect of any inaccuracy in or breach of any representation, warranty, covenant or
agreement contained in this Agreement shall in no way be limited by the fact that the act, omission, occurrence or other state of facts upon which any claim of any such inaccuracy or breach is based may also be the subject matter of any other
representation, warranty, covenant or agreement contained in this Agreement (or in any other agreement between the parties) as to which there is not inaccuracy or breach. 

10.8 Section Headings. The Section headings are for the convenience of the parties and in no way alter, modify, amend, limit, or
restrict the contractual obligations of the parties. 
 10.9 Severability. If any part of this Agreement is ruled to be
invalid, illegal, or unenforceable by a court or other body of competent jurisdiction, the remainder of this Agreement shall continue in full force and effect and shall be deemed modified to the minimum extent necessary to make it enforceable. If
any such ruling in question is subsequently overruled or obviated by legislative or other action, the severed provisions of this Agreement shall return to full force and effectiveness. 

10.10 Counterparts. This Agreement may be executed in two or more counterparts, which may be facsimile counterparts, each of
which shall be deemed to be an original, but all of which shall be deemed collectively one and the same instrument. 
 10.11 Export
Control. Licensee acknowledges and agrees that Brandeis is subject to United States laws and regulations controlling the export of technical data, computer software, laboratory prototypes and other commodities (including the Arms Export Control
Act, as amended and the Export Administration Act of 1979), and that its obligations hereunder are contingent on compliance with applicable United States export laws and regulations. The transfer 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

14 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
of certain technical data and commodities may require a license from the cognizant agency of the United States Government and/or written assurances by Licensee that Licensee shall not export data
or commodities to certain foreign countries, or to any individuals or entities on the U.S. Treasury Department’s List of Specifically Designated Nationals or the U.S. Commerce Department Table of Designated Orders without prior approval of such
agency. Brandeis neither represents that a license shall not be required nor that, if required, it shall be issued. 
 10.12
Marking. Licensee agrees to mark Licensed Products sold in the United States with all applicable United States patent numbers as appropriate. All Licensed Products shipped to or sold in other countries shall be marked in such manner as to
conform with the patent laws and practice of the country of manufacture or sale. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

15 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized officers as of the Effective Date. 
  

							
	BRI-ALZAN INC.	 	BRANDEIS UNIVERSITY
				
	By:	 	 /s/ Stacie Weninger
	 	 By:
	 	 /s/ Irving R Epstein

				
	Name:	 	Stacie Weninger	 	Name:	 	 Irving R Epstein, Ph.D.

				
	Title:	 	President	 	Title:	 	 Interim Executive Director

				
		 		 		 	Office of Technology Licensing

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

16 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 EXHIBIT A 

A.1 Royalty Rate. Beginning with the First Commercial Sale in any country, and on all sales thereafter of Licensed Products anywhere in
the world by any Seller, so long as the Patent Rights are in effect, Licensee shall pay Brandeis royalties for each Licensed Product sold by each Seller as follows: 

(i) [***] percent ([***]%) of the Net Sales Price of Licensed Products. 

(ii) One Royalty. Only one royalty under Section A.1 shall be due and payable to Brandeis by any Seller for any Licensed Product
regardless of the number of Patent Rights covering such Licensed Product. 
 A.2 License Maintenance Fees. Licensee shall pay to
Brandeis the following license maintenance fees on the dates set forth below. Such license maintenance fees are waived while the Research Agreement is in effect. 
  

					
	 Payment Date
	  	Amount due from
Licensee prior to Change of
Control	 	Amount due from
Licensee after Change of
Control
	 (i) January 1, 2013 and January 1, 2014
	  	$[***]	 	$[***]
	 (ii) January 1, 2015, and each January 1 thereafter until [***]
	  	$[***]	 	$[***]
	 (iii) January 1 of each year after [***]
	  	$[***]	 	$[***]

 License maintenance fees are nonrefundable; however, the license maintenance fee may be credited to running
royalties and sublicense payments subsequently due on Net Sales earned during the same calendar year, if any. License maintenance fees paid in excess of running royalties and sublicense payments due in such calendar year shall not be creditable to
amounts due for future years. 
 A.3 Milestone Payments. Licensee shall pay to Brandeis the following milestone payments due and
payable within [***] ([***]) days of the first occurrence of the following events: 
  

			
	 Milestone
	  	Milestone Amount
	 (i) [***]
	  	$[***]
	 (ii) [***]
	  	$[***]
	 (iii) [***]
	  	$[***]

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 A.4 Equity. 

(i) Initial Grant. Licensee shall issue a total of one hundred (100) shares of Common Stock of Licensee, $0.01 par value per share, (the
“Shares”) in the name of Brandeis. Such issuance shall be recorded on the Stock Transfer Ledger of Licensee on the Effective Date and the Shares shall be delivered to Brandeis within thirty (30) days of the Effective Date. 

Company represents to Brandeis that, as of the Effective Date, the aggregate number of Shares equals Five Percent (5%) of the Licensee’s
issued and outstanding Common Stock calculated on a “Fully Diluted Basis.” For purposes of this Section A.4, “Fully Diluted Basis” shall mean that the total number of issued and outstanding shares of the Licensee’s Common
Stock shall be calculated to include conversion of all issued and outstanding securities then convertible into common stock, the exercise of all then outstanding options and warrants to purchase shares of common stock whether or not then
exercisable, and shall assume the issuance or grant of all securities reserved for issuance pursuant to any Licensee stock or stock option plan in effect on the date of the calculation. 

(ii) Anti-Dilution Protection. [***]. 

(iii) Assignment of License Agreement. If Licensee assigns the License Agreement as permitted in Section 10.4, and such assignment
does not result in all of Licensee’s equity holders exchanging their equity in Licensee for new equity in the assignee, then, at Brandeis’ option in its sole discretion, Brandeis shall [***]. This provision shall apply to each and every
assignee permitted without the prior consent of Brandeis under Section 10.4. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 A.5 Sublicense Lump Sum Payments. In addition to the royalties provided for above,
Licensee shall pay Brandeis [***] percent ([***]%) (hereinafter “Lump Sum Percentage”) of all lump sum payments received from Sublicensees (hereinafter “Lump Sum Payments”), excluding any payments made specifically for
reimbursement of actual research support expenses, and excluding royalties on Net Sales, which are accounted for in Section A. 1, above. Such payments shall be made to Brandeis within [***] ([***]) days after Licensee receives any Lump Sum Payment
from a Sublicensee under any sublicense. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 EXHIBIT B 

Patent Rights 
 [***] 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 EXECUTION COPY 

FIRST AMENDMENT TO LICENSE AGREEMENT 

THIS FIRST AMENDMENT TO THE LICENSE AGREEMENT is made effective as of this 31 day of December, 2015 (this “Amendment”) by and
between Brandeis University, a not- for-profit corporation duly organized and existing under the laws of The Commonwealth of Massachusetts and having its principal place
of business at 415 South Street, Waltham, Massachusetts 02454-9110 (“Brandeis”), and BRI-Alzan Inc., a corporation duly organized and existing under the laws of the State of Delaware having its
offices at c/o F-Prime Inc., One Main Street, 13th Floor, Cambridge, Massachusetts 02142 (hereinafter referred to as “Licensee”). MeiraGTx Limited, a private limited company duly formed under the
laws of England and Wales, joins in this Amendment solely for the limited purposes set forth in Paragraph 2.a. 
 WHEREAS, Brandeis and
Licensee are parties to that certain License Agreement effective as of May 1, 2013 (the “License Agreement”); 
 WHEREAS,
Licensee is entering into that certain Agreement and Plan of Merger dated as of the date hereof (the “Merger Agreement”) by and among Licensee, MeiraGTx Acquisition Corporation, a Delaware corporation (“Merger Sub”), the
stockholders of Licensee comprised of F-Prime Inc. (f/k/a Fidelity Biosciences Corp.) (“Fidelity”), Gregory Petsko, Dagmar Ringe and Brandeis (collectively, the “Sellers”), Fidelity, solely
in its capacity as representative of the Sellers, and MeiraGTx Limited, a private limited company duly formed under the laws of England and Wales and the sole stockholder of Merger Sub (“Parent”), pursuant to which Licensee will merge with
and into Merger Sub with Licensee surviving the merger and thereby becoming a wholly-owned subsidiary of Parent (the “Merger”); 

WHEREAS, as part of the consideration for the Merger, Parent will have certain conditional obligations to make the Contingent Payments (as
defined in the Merger Agreement), subject to the terms and conditions of (and solely to the extent required by) the Merger Agreement; 

WHEREAS, Parent, in connection with the Merger, has requested certain changes to the License Agreement, to which its subsidiary will be a
party after the Merger; and 
 WHEREAS, in connection with the Merger and the acknowledgements herein below set forth in Paragraph 2,
Brandeis and Licensee are willing to amend the License Agreement in certain respects as herein set forth. 
 NOW, THEREFOR, in consideration
of the Merger Consideration (as defined in, and subject in all respects to the terms and conditions set forth in, the Merger Agreement) and the mutual promises and agreements herein set forth, Brandeis and Licensee do hereby agree as follows: 

1. Definitions. Capitalized terms used, but not otherwise defined in this Amendment, shall have the meanings assigned to such terms
under the License Agreement. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 2. Acknowledgments. 

(a) Parent. Parent hereby acknowledges and agrees that if (i) the License Agreement is assigned after the consummation of the Merger such
that another Person, who is not a direct or indirect Affiliate of Parent has assumed Licensee’s obligations to Brandeis under the License Agreement (as amended by this Amendment) (each, a “Permitted Transferee”), and (ii) Parent
does not also assign its obligations to make the Contingent Payments under the Merger Agreement to such Permitted Transferee or a direct or indirect Affiliate thereof, then (x) Parent’s then-remaining obligations under the Merger Agreement
to make the Contingent Payments (subject to, and in accordance with, the terms and conditions of the Merger Agreement) shall not be affected by such assignment of the License Agreement. For greater clarity, nothing in this Section 2(a) shall
alter the requirements for a valid assignment under Section 7.7 of the Merger Agreement. 
 (b) Brandeis. Solely with respect to the
transfer of the License Agreement in connection with the Merger, Brandeis agrees to waive application of the higher license maintenance fees for a Change of Control set forth in Section A.2 of Exhibit A of the License Agreement and that the license
maintenance fees set forth in column captioned “Amount due from Licensee prior to Change of Control” shall remain in effect immediately following the consummation of the Merger. Neither Parent nor any Person that is an Affiliate of Parent
(which shall include the Licensee) shall be bound to issue or otherwise deliver to Brandeis by virtue of the Merger at any time from and after the completion of the Merger any equity other than the Parent Shares allocated to Brandeis on Schedule
2.1.5 to the Merger Agreement. Notwithstanding anything to the contrary in the License Agreement, Brandeis hereby consents to the Merger. Brandeis further acknowledges and agrees that from and after the completion of the Merger, the License
Agreement, as amended by this Amendment, shall remain and continue in full force and effect. 
 (c) Licensee. Licensee hereby acknowledges
and agrees that the consummation of the Merger does not terminate or otherwise alter or affect its obligations to Brandeis under the terms and conditions of the License Agreement, as amended by this Amendment, which shall remain and continue in full
force and effect from and after the completion of the Merger. 
 3. Amendments to License Agreement. Brandeis and Licensee hereby
amend the License Agreement as follows: 
 (a) The definition of the term “Change of Control” contained in Section 1.4 of the
License Agreement is hereby amended to add the following after at the end of the paragraph: 
 A “Change of Control” shall not
include a public offering of capital stock of Licensee or of the share capital of Parent or of a holding company of Parent, so long as Parent or such holding company of Parent is an Affiliate of Licensee. 

(b) The definition of the term “Gross Sales” contained in Section 1.7 of the License Agreement is hereby deleted and amended and
restated in its entirety as follows: 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

2 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 “Gross Sales” or “Gross Sales Price” means for any
arm’s length sale, transfer, dispositions or other dealing to a customer by a Seller, the Gross Sales Price shall be the gross amount invoiced by the Seller for the sale, transfer or other disposition of or dealing with a Licensed Product. 

Transfer of a Licensed Product within the Licensee or between Licensee, Sublicensee or an Affiliate shall not be considered a
sale, commercial use or disposition for the purpose of the foregoing paragraphs; in the case of such transfer the Gross Sales Price shall be based on sale of the Licensed Product by the transferee. If a Seller commercially uses or disposes of any
Licensed Product by itself other than in an arm’s length sale to a bona fide customer, the Gross Sales Price hereunder shall be the price which would be then payable in an arm’s length transaction. [***] The “Gross Sales” or
“Gross Sales Price” shall not include transfers or dispositions for charitable, compassionate, promotional, pre- clinical, clinical, regulatory, or governmental purposes. 

For any sale of a Licensed Product to which the United States government is entitled to a royalty-free right pursuant to 35 USC
202(c)(paragraph 4), [***]. 
 (c) The definition of the term “Net Sales” contained in Section 1.12 of the License Agreement
is hereby deleted and amended and restated in its entirety as follows: 
 “ “Net Sales” or “Net Sales
Price” means the Gross Sales Price received by a Seller less (to the extent appropriately documented) the following amounts actually paid out by a Seller or credited against the amounts received by it from the sale or distribution of Licensed
Product: 
 (a) credits, allowances and price adjustments for damaged, defective or rejected Licensed Products or for the
rejection or return of Licensed Products previously sold; 
 (b) rebates, chargeback payments and trade, cash and quantity
discounts to purchasers allowed and taken; 
 (c) amounts for transportation, insurance, handling or shipping charges or
directly related to the sale or distribution of Licensed Product and listed on the invoices or purchase order for such Licensed Product; 

(d) taxes, tariffs, duties and other governmental charges levied on or measured by the sale of Licensed Products, whether
absorbed by the Seller or paid by the purchaser so long as the Seller’s price is reduced thereby, but not franchise or income taxes of any kind whatsoever; 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

3 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 For Net Sales of a Licensed Product sold or supplied as a Combination Product, the Net Sales
of such a Combination Product will be determined, subject to the provisions set forth below in this Section 1.12, by multiplying the actual Net Sales of such Combination Product in a particular country in the Territory by the fraction of
A/(A+B), where A is the average Gross Sales billed or invoiced per unit of such Licensed Product in such country in the Territory during the period in respect of which Net Sales are being calculated of the Licensed Product sold separately and B is
the total average Gross Sales billed or invoiced per unit in such country in the Territory of the other active ingredient (including a biologic product) or device included in the Combination Product during the period in respect of which Net Sales
are being calculated, when sold separately. If neither the Licensed Product nor the other active ingredient (including a biologic product) or device included in the Combination Product are sold separately as a monotherapy during the period in
respect of which Net Sales are being calculated, then the fair market value of the other active ingredient (including a biologic product) or device included in the Combination Product that is to be deducted from the Net Sales of the Combination
Product in determining the Net Sales of the Licensed Product contained in the Combination Product shall be equal to the fair market value of such other active ingredient (including a biologic product) or device included in the Combination Product as
determined in accordance with the provisions of the Merger Agreement for such Licensed Product. As used herein, a “Combination Product” means a product which comprises (a) a Product and (b) at least one other active ingredient
(including a biologic product) or medical device.” 
 Subject to the above, Net Sales shall be calculated in accordance
with United Kingdom generally accepted accounting principles (or U.K. GAAP), consistently applied with the past practice of the Licensee and its Affiliates.” 

(d) Exhibit A to the License Agreement is hereby deleted in its entirety and amended, restated and replaced in its entirety with Exhibit A
attached to this Amendment. On and after the Effective Date of this Amendment, each reference to Exhibit A in the License Agreement shall mean and be a reference to Exhibit A attached to this Amendment. 

(e) Exhibit B to the License Agreement is hereby deleted in its entirety and amended, restated and replaced in its entirety with Exhibit B
attached to this Amendment. On and after the Effective Date of this Amendment, each reference to Exhibit B in the License Agreement shall mean and be a reference to Exhibit B attached to this Amendment. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

4 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 (f) Section 3.1(a) of the License Agreement is hereby amended to delete the phrase
“During the last [***] ([***]) months of the Research Agreement Term,” and to substitute the following phrase: “On or prior to June 30, 2016,” 

(g) Section 3.3 of the License Agreement is hereby amended to add the following after at the end of the paragraph: 

As of the Effective Date of this Amendment, it is understood that Licensee does not have any obligations, financial or otherwise, under the
Research Agreement. 
 (h) The address for notice for Licensee set forth in Section 10.3 of the License Agreement is amended as follows:

 “To Licensee: 
 c/o
MeiraGTx Limited 
 450 East 29th Street, 5th Floor 

New York, New York 10016 
 Attn:
[***]” 
 (i) The second sentence of Section 10.4 of the License Agreement is hereby deleted and amended and restated in its
entirety as follows: 
 “Notwithstanding the foregoing, this Agreement may be assigned by Licensee without the consent of Brandeis
(a) to an Affiliate, and (b) in connection with the transfer or sale, directly or indirectly, of all or substantially all of the assets and business of Licensee to a third party, whether by merger, sale of stock, sale of all or
substantially all assets, consolidation, recapitalization, or other business combination, provided that, with respect to (a) and (b) above, (i) Licensee is in good standing under the laws of its jurisdiction of incorporation or formation,
(ii) any such permitted assignee (1) has total net assets (total assets minus total liabilities) reflected on its balance sheet as of the end of the then most recently completed fiscal year that are equal to or greater than Licensee’s
total net assets as reflected on a balance sheet as of the end of Licensee’s then most recently completed fiscal year, (2) (A) is not the subject of any litigation or proceeding (including, but not limited to arbitration), in law or in equity,
and (B) there are no proceedings or known governmental investigations before any administrative or governmental authority (including any commission), pending or threatened against such permitted assignee, in each case with respect to clauses
(A) and (B), that would reasonably be expected to impair its ability to fulfill its obligations under the License Agreement, and (3) shall assume all obligations of its assignor under this Agreement in writing, and (iii) Licensee or
assignees shall deliver a fully executed copy of such assumption of obligations to Brandeis within [***] ([***]) days of completing the assignment. For purposes of this Section 10.4, “known” shall mean “known by such permitted
assignee.”” 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

5 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 4. Representations . Brandeis hereby represents and warrants to the Licensee, and
Licensee hereby represents and warrants to Brandeis, that this Amendment has been duly authorized and executed and delivered by such party and is a legal, valid, binding and enforceable obligation of such party, except as such enforceability may be
limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity. 

5. No Implied Amendments . Except as herein provided, the License Agreement shall remain in full force and effect and are ratified in
all respects. On and after the Effective Date of this Amendment, each reference in the License Agreement to “this Agreement,” “hereunder,” “hereof,” “herein,” or words of like import, and each reference to the
License Agreement in any other agreements, documents or instruments executed and delivered from and after the Effective Date of this Amendment, shall mean and be a reference to the License Agreement, as amended by this Amendment. 

6. Governing Law . This Amendment shall be construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to
the choice of laws rules thereof, and the obligations, rights and remedies of the parties hereunder shall be determined in accordance with such laws. Any legal suit, action or proceeding against any of the parties hereto arising out of or relating
to this Amendment shall only be instituted in any federal or state court located in Boston, Massachusetts, and each party hereby irrevocably submits to the exclusive jurisdiction of any such court in any such suit, action or proceeding. The parties
hereby agree to venue in such courts and hereby waive, to the fullest extent permitted by law, any claim that any such action or proceeding was brought in an inconvenient forum. Each of the parties hereby irrevocably waives all right to trial by
jury in any action, proceeding or counterclaim arising out of or relating to this Amendment. 
 7. Entire Agreement . This Amendment
(including the Exhibit hereto) together with the License Agreement and the Merger Agreement constitute the entire agreement among the parties with respect to the subject matter hereof and supersede all prior agreements, understandings and
undertakings, both written and oral, among the parties, or any of them, with respect to the subject matter hereof. 
 8. Counterparts
.. This Amendment may be executed in several counterparts, each of which will be deemed an original but all of which will constitute one and the same. 

9. Effective Date . For the avoidance of doubt, this Amendment shall be effective upon the completion of the Merger pursuant to the
Merger Agreement as evidenced by the filing by Licensee of a certificate of merger with the Secretary of State of the State of Delaware. 
 [
Remainder of page intentionally left blank. ] 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

6 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly
authorized officers as of the Effective Date. 
  

							
	WITNESS/ASSEST:	 	BRANDEIS UNIVERSITY
				
	By:	 	 /s/ Diane P. Walsh
	 	By:	 	 /s/ Rebecca Menapace

				
	Name:	 	Diane P. Walsh	 	Name:	 	Rebecca Menapace
				
	Title:	 	 Dept. Coordinator, OTL
	 	Title:	 	 Associate Provost for Innovation

		 	Brandeis University	 		 	Executive Director, OTL
		
		 	BRI-ALZAN INC.
				
	By:	 	 /s/ Allan S. Galper
	 	By:	 	 /s/ Stacie Weninger Barnes

				
	Name:	 	Allan S. Galper	 	Name:	 	Stacie Weninger Barnes
				
	Title:	 	Secretary	 	Title:	 	President
		
		 	 For the limited purposes set forth in Paragrah 2.a. of this Amendment:

 
 MEIRAGTx LIMITED

				
	By:	 	 /s/ Richard Giroux
	 	By:	 	 /s/ Zandy Forbes

				
	Name:	 	Richard Giroux	 	Name:	 	Zandy Forbes
				
	Title:	 	COO	 	Title:	 	CEO

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 EXHIBIT A 

A.l Royalty Rate. Beginning with the First Commercial Sale in any country, and on all sales thereafter of Licensed Products anywhere in the world by any
Seller, so long as the Patent Rights are in effect, Licensee shall pay Brandeis royalties for each Licensed Product sold by each Seller as follows: 

(i) [***] percent ([***]%) of the Net Sales Price of Licensed Products. 

(ii) One Royalty. Only one royalty under Section A.l shall be due and payable to Brandeis by any Seller for any Licensed Product
regardless of the number of Patent Rights covering such Licensed Product. 
 A.2 License Maintenance Fees. Licensee shall pay to Brandeis the
following license maintenance fees on the dates set forth below. 
  

					
	 Payment Date
	  	Amount due from Licensee
prior to Change of Control	 	Amount due from Licensee
after Change of Control
	 (i) January 1, 2016, and each January 1 thereafter until [***]
	  	$[***]	 	$[***]
	 (ii) January 1 of each year after [***]
	  	$[***]	 	$[***]

 License maintenance fees are nonrefundable; however, the license maintenance fee may be credited to running royalties and
sublicense payments subsequently due on Net Sales earned during the same calendar year, if any. License maintenance fees paid in excess of running royalties and sublicense payments due in such calendar year shall not be creditable to amounts due for
future years. 
 A.3 Milestone Payments. Licensee shall pay to Brandeis the following milestone payments due and payable within [***] ([***]) days of
the first occurrence of the following events: 
  

			
	 Milestone
	  	Milestone Amount
	 (i) [***]
	  	$[***]
	 (ii) [***]
	  	$[***]
	 (iii) [***]
	  	$[***]

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 A.4 Sublicense Lump Sum Payments. In addition to the royalties provided for above, Licensee shall pay
Brandeis [***] percent ([***]%) (hereinafter “Lump Sum Percentage”) of all lump sum payments received from Sublicensees (hereinafter “Lump Sum Payments”), excluding any payments made specifically for reimbursement of actual
research support expenses, and excluding royalties on Net Sales, which are accounted for in Section A.l, above. Such payments shall be made to Brandeis within [***] ([***]) days after Licensee receives any Lump Sum Payment from a Sublicensee under
any sublicense. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 EXHIBIT B 

[***] 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}]]